Search clinical trials for: HLA-A*0201/p53 aa264-272

Total 471346 results

Altor BioScience
National Cancer Institute (NCI)

Terminated

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Solid Tumors

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Altor BioScience
James and Esther King Biomedical Research Program

Unknown

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

United States
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Cue Biopharma

Recruiting

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer

United States
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Altor BioScience
National Cancer Institute (NCI)

Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME Positive

United States
University of California, San Francisco
Parker Institute for Cancer Immunotherapy; The V Foundation; Alliance for Cancer...

Recruiting

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018)

Diffuse Midline Glioma, H3 K27M-Mutant

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

Prostate Neoplasms | Prostate Specific Antigens

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1

United States
Diwakar Davar
Immunocore Ltd

Not yet recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Uveal Melanoma

United States
BrightPath Biotherapeutics

Completed

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Melanoma

United States
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
National Cancer Institute (NCI)

Withdrawn

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Sarcoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Colon Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Pancreatic Cancer

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Cytomegalovirus Vaccine in Healthy Participants

Precancerous/Nonmalignant Condition

United States
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Northwestern University

Terminated

An In-vitro Standardization of B Cell Elispot Assays

Transplant Sensitization | Panel Reactive Antibody | Sensitization to HLA Antigens

United States
University of Cincinnati
Millennium Pharmaceuticals, Inc.

Completed

Desensitization in Kidney Transplantation

HLA Sensitization

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Donor | Hematopoietic Cell Transplant Recipient | HLA-A*0201 Positive Cells Present

United States
University Hospital, Brest

Completed

NGS for HLA Typing of Donors and récipients oh Hematopoietic Stem Cells (NGS HLA)

Next Generation Sequencing for HLA Typing

France
Celltrion

Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Poland
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Mansoura University

Recruiting

The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence

Death | Wilms Tumor | Relapse

Egypt
Moy-Fincher-Chipps Facial Plastics and Dermatology

Unknown

To Evaluate and Compare p53 Epidermal Expression in Healthy Volunteers 3 Months After Treatment With a 2,940-nm Fractional Ablative Erbium Laser and Topical DNA Repair Enzymes

p53 Expression
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors (rAd-p53)

Advanced Oral and Maxillofacial Malignant Tumors

China
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Universidad Europea de Madrid

Recruiting

Continuous Subcutaneous Glucose Monitoring in Critical Patients

Hyperglycemia | Hypoglycemia | Diabetes | Critical Care | Critically Ill Patients

Spain
Sechenov University
Pirogov Russian National Research Medical University

Recruiting

Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population

Bullous Pemphigoid | Stevens-Johnson Syndrome | Toxic Epidermal Necrolyses | Pemphigus

Russian Federation
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Chronic Lymphocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer

United States, Switzerland, China, France
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

Advanced Malignant Thyroid Tumors

China
Dren Bio
Novotech (Australia) Pty Limited

Recruiting

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma

Australia, Hong Kong, Korea, Republic of, Singapore, Taiwan
Leiden University Medical Center
University Medical Center Groningen

Completed

Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer (CHIP)

Recurrent Ovarian Cancer

Netherlands
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
Shanghai Changzheng Hospital

Unknown

Arsenic Trioxide for Structural p53 Mutations

Refractory Cancer | Arsenic Trioxide | p53 Mutations | Intractable Cancer

China

Search clinical trials for: HLA-A*0201/p53 aa264-272

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations